Surgeon and medical oncologist peer network effects on the uptake of the 21‐gene breast cancer recurrence score assay

Autor: Andrew P Schaefer, Erika L. Moen, Ronnie Zipkin, Mary D. Chamberlin, Tracy Onega, Alistair J. O'Malley
Jazyk: angličtina
Rok vydání: 2021
Předmět:
0301 basic medicine
Oncology
Cancer Research
medicine.medical_specialty
Psychological intervention
Breast Neoplasms
lcsh:RC254-282
Peer Group
Odds
genetic testing
03 medical and health sciences
0302 clinical medicine
Breast cancer
breast cancer
Internal medicine
medicine
Biomarkers
Tumor
Humans
Radiology
Nuclear Medicine and imaging
Precision Medicine
Genetic testing
Original Research
Aged
Retrospective Studies
Aged
80 and over
medicine.diagnostic_test
business.industry
Gene Expression Profiling
Clinical Cancer Research
Retrospective cohort study
Odds ratio
medicine.disease
lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens
United States
030104 developmental biology
030220 oncology & carcinogenesis
Cohort
medicare
oncologists
Female
Neoplasm Recurrence
Local
surgeons
Oncotype DX
business
Zdroj: Cancer Medicine, Vol 10, Iss 4, Pp 1253-1263 (2021)
Cancer Medicine
ISSN: 2045-7634
Popis: Background Drivers behind the adoption of gene expression profiling in breast cancer oncology have been shown to include exposure to physician colleagues’ use of a given genomic test. We examined adoption of the Oncotype DX 21‐gene breast cancer recurrence score assay (ODX) in the United States after its incorporation into clinical guidelines. The influence of patient‐sharing ties and co‐location with prior adopters and the role of these potential exposures across medical specialties on peers’ adoption of the test were examined. Methods We conducted a retrospective cohort study of women with incident breast cancer using a 100% sample of fee‐for‐service Medicare enrollee claims over 2008–2011. Peer networks connecting medical oncologists and surgeons treating these patients were constructed using patient‐sharing and geographic co‐location. The impact of peer connections on the adoption of ODX by physicians and testing of patients was modeled with multivariable hierarchical regression. Results Altogether, 156,229 women identified with incident breast cancer met criteria for cohort inclusion. A total of 7689 ODX prescribing physicians were identified. Co‐location with medical oncologists who adopted the test in the early period (2008–2009) was associated with a 1.38‐fold increase in the odds of a medical oncologist adopting ODX in 2010–2011 (95% CI = 1.04–1.83), as was co‐location with early‐adopting surgeons (odds ratio [OR] = 1.25, 95% CI = 1.00–1.58). Patients whose primary medical oncologist was linked to an early‐adopting surgeon through co‐location (OR = 1.17, 95% CI = 1.04–1.32) or both patient‐sharing and co‐location (OR = 1.17, 95% CI = 1.03–1.34) were more likely to receive ODX. Conclusions Exposure to surgeon early adopters through peer networks and co‐location was predictive of ODX uptake by medical oncologists and testing of patients. Interventions focused on the role of surgeons in molecular testing may improve the implementation of best practices in breast cancer care.
Surgeons have been engaged in the development of clinical algorithms involving postoperative molecular testing criteria for breast cancer patients, though promotion efforts and research into the dissemination of these technologies has primarily been focused on medical oncologists. This study demonstrates that peer influence from both early‐adopting surgeons and medical oncologists may have facilitated the uptake of the Oncotype DX recurrence score assay by their medical oncologist peers. Initiatives aimed at improving efficient and equitable incorporation of genomic and molecular innovations into breast cancer care would benefit from engaging surgeons as well as medical oncologists.
Databáze: OpenAIRE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje